Core Insights - The company reported a strong FY 2025 with a constant-currency revenue growth of 24.2%, slightly above the prior guidance of 20% to 23% [2][7] - A leadership transition occurred with co-founder Gordon Sanghera stepping down as CEO, succeeded by Francis Van Parys, while Sanghera will remain as an advisor until early 2027 [4][8] - The company is focusing on applied markets, which now represent approximately 34% of revenue, with significant growth in clinical (59%), biopharma (30%), and applied industrial (27%) segments [1][7] Financial Performance - FY 2025 revenue from life science research tools constituted 66% of total revenue, growing by 15% [1] - The reported gross margin for FY 2025 was 58.6%, with a "see-through" gross margin closer to 61% [6][10] - The adjusted EBITDA loss improved by £31.2 million (26%), with a target for adjusted EBITDA breakeven in 2027 and cash flow breakeven in 2028 [6][14] Strategic Focus and Product Portfolio - The company is realigning its product portfolio, discontinuing P2 Solo and pausing the Elise platform, while increasing focus on integrated systems like P2i and P24 [8][21] - A strategic review identified $13 billion to $14 billion in higher-priority segments, shaping resource allocation and product roadmap decisions [18] - The company aims to enhance its value proposition through direct sequencing of native DNA and RNA, real-time data generation, and avoiding batching requirements [9] 2026 Guidance - For FY 2026, the company guided for revenue growth of 21% to 25%, with a gross margin target of 62% [22][24] - Growth is expected to be strongest in the Americas, with over 50% of revenue from applied segments, while challenges are anticipated in EMEA and APAC due to contract roll-offs and local competition [23] - The company expects adjusted OpEx growth of 0% to 5%, reflecting benefits from recent restructuring and efficiency initiatives [24]

Core Insights - Oxford Nanopore Technologies achieved a 24% constant currency revenue growth for the year, surpassing its initial guidance of 20%-23% [3][7][4] - The company experienced significant growth across various product segments, particularly in clinical and biopharma markets, despite facing challenges such as NIH funding uncertainty and geopolitical issues in China [2][4][8] Revenue Growth - Clinical revenue grew over 60%, biopharma revenue increased by 30%, applied industrial revenue rose by 27%, and research revenue grew by 15% [2][7] - The Americas region showed strong momentum in the second half of the year, contributing to overall growth [3][7] Regional Performance - The Americas now derive more than half of their revenue from non-research segments, contrasting with EMEA where research remains a larger share [1] - In EMEA, academic growth exceeded 20% and clinical growth surpassed 50% [10] - Asia-Pacific faced challenges due to the roll-off of a significant contract and competitive pressures from local players, with China representing about 8% of total revenue [8][10] Product Dynamics - Higher-throughput devices like PromethION and P2i are becoming central for whole-genome and scale use cases, as customers increasingly skip earlier devices [5][11] - The MinION flow cell is suitable for small genomes and targeted sequencing, while the PromethION flow cell supports whole human genome sequencing [9][11] Financial Position - The company ended the year with GBP 302 million in cash, ahead of market expectations, and improved cash flow by shifting to a CapEx sales model [6][17][18] - Inventory optimization contributed to cash improvement, with over GBP 100 million in inventory at year-end [19] Cost Management and Future Targets - The company reduced headcount by 5% and is targeting EBITDA breakeven by 2027 and cash flow breakeven by 2028 [20][21] - Controlled operating expense growth and gross margin improvement are emphasized as key components to achieving these targets [21]

Core Insights - Oxford Nanopore Technologies will present its advancements in human genetics at the ASHG 2025 industry session, focusing on integrated analysis for better disease insights [1] Group 1: Company Developments - The presentation will showcase the unique capabilities of the PromethION platform in delivering comprehensive whole genomes and methylomes [1]